Genetic diversity of HCV among various high risk populations (IDAs, thalassemia, hemophilia, HD patients) in Iran

Asian Pacific Journal of Tropical Medicine

Volumn 6, Issue 7, 2013, Pages 556-560

  Rafiei, A ^a   Darzyani, Azizi M ^a   Taheri, S ^a   Haghshenas, M R ^a   Hosseinian, A ^b   Makhlough, A ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

HCV; Hemodialysis; Hemophilia; Intravenous drug addicts; Iran; Thalassemia

Indexed keywords

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; IRAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PRIORITY JOURNAL; RISK FACTOR; THALASSEMIA;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC VARIATION; GENOTYPE; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IRAN; MALE; PREVALENCE; RISK FACTORS; RNA, VIRAL; SUBSTANCE ABUSE, INTRAVENOUS; THALASSEMIA;

EID: 84879021077     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(13)60096-6     Document Type: Article

References (37)

1. Theodore Sy T, Jamal MM Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3:41-46.
2. Chen SL, Morgan TR The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3(2):47-52.
3. Mansour-Ghanaei FFM, Jafarshad R, Joukar F, Pourtahmasbi A, Bahari-Moghaddam A Seroprevalence of hepatitis B and C among residents of guilan nursing home. Hepat Mon 2007, 7(3):139-141.
4. Dong ZX, Zhou HJ, Wang JH, Xiang XG, Zhuang Y, Guo SM, et al. Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: Correlation with patients characteristics and clinical parameters. J Dig Dis 2012, 13(11):564-570.
5. Quirino A, Giancotti A, Barreca GS, Lamberti AG, Caroleo B, Liberto MC, et al. Eleven-year distribution pattern of hepatitis C virus in southern Italy. J Pathog 2012, 2012:631095.
6. Ferenci P Optimal treatment duration for patients with HCV genotype 1 infection. J Viral Hepat 2012, (Suppl 1):7-13.
7. Alavian SM, Fallahian F Epidemiology of hepatitis C in Iran and the world. Shiraz E Med J 2009, 10(4).
8. Bagheri Lankarani K, Mehrabani D, Behzad-Behbahani A, Serati A, Ardebili M, Yousefi M, et al. Hepatitis C virus genotypes in shiraz, southern Iran. Hepatitis Monthly 2009, 9(2):122-127.
9. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005, 18:52-61.
10. Griveas I, Germanidis G, Visvardis G, Morice Y, Perelson AS, Pawlotsky JM, et al. Acute hepatitis C in patients receiving hemodialysis. Ren Fail 2007, 29:731-736.
11. Amini S, Abadi MMFM, Alavian SM, Joulaie M, Ahmadipour MH Distribution of hepatitis C virus genotypes in Iran: a population-based study. Hepatitis Monthly 2009, 9:95-102.
12. Shahrokhi N, Farzanehkhah M, Ghorishi SM, Biglari S, Salehinodeh AR, Sarafnejad A, et al. Genotyping pattern among Iranian HCV positive patients. Iranian J Publ Health 2010, 39(2):39-44.
13. Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, Shabestari AN, Hassanpour G, et al. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol 2012, 157(10):1959-1965.
14. Zarkesh-Esfahani SH, Kardi MT, Edalati M Hepatitis C virus genotype frequency in Isfahan province of Iran: a descriptive cross-sectional study. Virol J 2010, 7:69.
15. Zali MR, Mayumi M, Raoufi M, Nowroozi A Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J 2000, 6(2-3):372-373.
16. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion Today 2009, 49(10):2195-2199.
17. Samimi-Rad K, Shahbaz B Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia 2007, 13:156-163.
18. Sereno S, Perinelli P, Laghi V Changes in the preva-lence of hepatitis C virus genotype among Italian injection drug users-relation to period of injection started. J Clin Virol 2009, 45:354-357.
19. Micalessi MI, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R Distribution of hepatitis C virus genotypes among injecting drug users in contract with treatment centers in Belgium 2004-2005. J Med Virol 2008, 80:640-645.
20. Samimi-Rad K, Nategh R, Malekzadeh R, Norder H, Magnius L Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol 2004, 74:246-252.
21. Ahmadi Pour MH, Keivani H, Sabahi F, Alavian SM Determination of HCV Genotypes, in Iran by PCR-RFLP. Iranian J Publ Health 2006, 35(4):54-61.
22. Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Virol J 2011, 8:466.
23. Waheed AY, Shafi T, Safi SZ, Qadri I Hepatitis C virus genotypes in Pakistan: a systemic review. Virol J 2011, 8:433.
24. Rehan HS, Manak S, Yadav M, Deepinder, Chopra D, Wardhan N Diversity of genotype and mode of spread of hepatitis C virus in Northern India. Saudi J Gastroenterol 2011, 17(4):241-244.
25. Alfaresi MS Prevalence of hepatitis C virus (HCV) genotypes among positive UAE patients. Mol Biol Rep 2011, 38(4):2719-2722.
26. Altuglu I, Ozacar T, Erensoy S Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008, 12(3):239-244.
27. Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, et al. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009, 104(11):1881-1890.
28. White PA, Zhai X, Marinos G, Rawlinson WD Mixed viral infection identified using heteroduplex mobility analysis (HMA). Virology 2000, 271:382-389.
29. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
30. Hairul Aini H, Mustafa MI, Seman MR, Nasuruddin BA Mixed-genotypes infections with hepatitis C virus in hemodialysis subjects. Med J Malaysia 2012, 67(2):199-203.
31. Rezvan H, Abolghassemi H, Kafiabad SA Transfusion-transmitted infections among multitransfused patients in Iran: a review. Transfusion Med 2007, 17:425-433.
32. Esteban JI, Sauleda S, Quer J The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008, 48(1):148-162.
33. Ríos-Olivares E, Yamamura Y, Gómez MA, Guzmán L, Rodríguez N, Fernández D, et al. HCV genotype analysis in HCV-HIV-co-infected Puerto Ricans who are injecting drug users: undetermined and mixed infections. Cell Mol Biol 2001, 47(6):1017-1024.
34. Lopes CL, Teles SA, Espírito-Santo MP, Lampe E, Rodrigues FP, Motta-Castro AR, et al. Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev Saúde Pública 2009, 43(Supl. 1).
35. Oliveira MLA, Telles PR, Hacker MA, Oliveira SAN, Miguel JC, Yoshida CFT, et al. Epidemiological and genetic analyses of hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol 2009, 44(3):200-206.
36. Demetriou VL, van de Vijver DA, Hezka J, Kostrikis LG, Kostrikis LG Hepatitis C infection among intravenous drug users attending therapy programs in Cyprus. J Med Virol 2010, 82:263-270.
37. Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol 2012, 84(7):1097-1105.